Inventor · disambiguated record
Zhiyong Yu
Also filed as: YU ZHIYONG
14 granted patents·18 pending applications·81 citations·filing 2015–2025
90Inventor score
Files withINCYTE CORP18RQX PHARMACEUTICALS INC5ADLAI NORTYE BIOPHARMA CO LTD3XIAMEN BIOTIME BIOTECHNOLOGY CO LTD3HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD1
Top patents by PatentIndex Score
32 records- 0198US11718605B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Aug 8, 2023·11 cites·28 claims
- 0298US11465981B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Oct 11, 2022·18 cites·28 claims
- 0395US11753413B2Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitorsINCYTE CORP·Filed 2021·Granted Sep 12, 2023·5 cites·38 claims
- 0495US9695168B2Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Jul 4, 2017·27 cites·63 claims
- 0594US11673894B2Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitorsINCYTE CORP·Filed 2020·Granted Jun 13, 2023·4 cites·25 claims
- 0693US10640503B2Imidazopyridines and imidazopyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2018·Granted May 5, 2020·7 cites·66 claims
- 0788US11168089B2Fused pyrimidine derivatives as A2A / A2B inhibitorsINCYTE CORP·Filed 2019·Granted Nov 9, 2021·5 cites·36 claims
- 0880US12091398B2PD-L1 antagonist compoundADLAI NORTYE BIOPHARMA CO LTD·Filed 2020·Granted Sep 17, 2024·2 cites·29 claims
- 0980US2023357255A1Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2023·Application pending·0 cites
- 1079US10047086B2Imidazopyridines and imidazopyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2017·Granted Aug 14, 2018·2 cites·65 claims
- 1175US2025313567A1Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2025·Application pending·0 cites
- 1275US2024360140A1Fused pyrazine derivatives as a2a / a2b inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 1368US2023133817A1Macrocyclic broad spectrum antibioticsRQX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1468US2023133667A1Macrocyclic broad spectrum antibioticsRQX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1564US2025367193A1Bifunctional compounds containing substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathwayNIKANG THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1662US2018273519A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2017·Application pending·0 cites
- 1762US2020283423A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Application pending·0 cites
- 1860US11873304B2Fused pyrimidine derivatives as A2A/A2B inhibitorsINCYTE CORP·Filed 2021·Granted Jan 16, 2024·0 cites·44 claims
- 1960US2017174671A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2016·Application pending·0 cites
- 2060US2019292188A1Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2019·Application pending·0 cites
- 2159US2025304717A1Camptothecin derivative and ligand-drug conjugateHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2255US2018179179A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2017·Application pending·0 cites
- 2354US2021198316A9Macrocyclic broad spectrum antibioticsRQX PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2453US2024368147A1Cyclin k degraderADLAI NORTYE BIOPHARMA CO LTD·Filed 2022·Application pending·0 cites
- 2553US2018016260A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2017·Application pending·0 cites
- 2653US2024285640A1Combination therapy for treating pik3ca-mutated cancerADLAI NORTYE BIOPHARMA CO LTD·Filed 2021·Application pending·0 cites
- 2752US2018327367A1Macrocyclic broad spectrum antibioticsRQX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2846US12410188B2Adenosine receptor antagonistXIAMEN BIOTIME BIOTECHNOLOGY CO LTD·Filed 2020·Granted Sep 9, 2025·0 cites·4 claims
- 2943US2022339160A1Adenosine receptor antagonistXIAMEN BIOTIME BIOTECHNOLOGY CO LTD·Filed 2020·Application pending·0 cites
- 3041US11591328B2Highly active CSF1R inhibitor compoundXIAMEN BIOTIME BIOTECHNOLOGY CO LTD·Filed 2019·Granted Feb 28, 2023·0 cites·20 claims
- 3139US11191798B2Extracts of Andrographis paniculata, methods for preparation and use thereofNUTRITION SCIENCE PARTNERS LTD·Filed 2017·Granted Dec 7, 2021·0 cites·15 claims
- 3237US11072635B2Macrocyclic broad spectrum antibioticsRQX PHARMACEUTICALS INC·Filed 2016·Granted Jul 27, 2021·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when Zhiyong Yu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →